At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
Limitlessother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Investigate the Safety and Efficacy of an NAD+ Boosting Investigational Product Together With a Low Carbohydrate Diet in an Adult Population With Mild Hypertension and Eligible for Normal-standard-of-care
In Brief
A Phase 2 clinical trial evaluating Limitless for Hypertension. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the safety and efficacy of Limitless, in combination with a low-carbohydrate diet, after 30 days of supplementation in an adult population. Changes from baseline to Day 30 post-supplementation on several parameters of vascular function will be examined and safety outcomes will be determined.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
CountriesCanada
CollaboratorsKGK Science Inc.
Timeline
Phase 2CompletedFinished
2023202420252026
Enrollment StartMar 2022
First PostedMar 2022
Primary CompletionSep 2022
Study CompletionOct 2022
TodayJul 2026
First PostedMar 28, 2022
Enrollment StartMar 17, 2022
Primary CompletionSep 28, 2022
Study CompletionOct 27, 2022
TodayJul 1, 2026
Enrollment to primary: 6 monthsPosted 4.3 years ago
Interventions
Limitlessother
Participants will be instructed to take Limitless for 30 days.